Project Grant R01CA289514
Award Date
9/11/24
Completion Date
8/31/29
Dollars Obligated
$852K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded a $900,625.00 Project Grant to The Johns Hopkins University on July 1, 2024 under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant will fund research on "The Role of Organismal Aging and the Plantar Skin Microenvironment in Acral Melanoma Progression." This research aims to investigate how biological aging and the skin microbiome impact the progression of acral melanoma, a rare form of skin...
This Project Grant award of $1,824,208, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research focused on understanding the molecular mechanisms driving melanoma progression and tumor immune evasion. The Wistar Institute of Anatomy and Biology, the primary awardee, will lead this 5-year study to investigate how the transcription factor TFEB regulates melanoma cell plasticity and impacts the tumor microenvironment. A sub-award to the University of...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $198,103 to New York University School of Medicine to investigate the role of the immune microenvironment in melanoma bone metastasis. The project aims to elucidate the mechanisms by which melanoma cells infiltrate and modify the bone microenvironment, and how they communicate with immune cells, in order to improve understanding of melanoma bone disease...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $442,236 to the University of Alabama at Birmingham to investigate the role of the YTHDF1 RNA-binding protein in driving melanoma metastasis. The research aims to determine how YTHDF1 promotes melanoma cell anoikis resistance and suppresses natural killer cell-mediated anti-tumor immunity, with a focus on the downstream mediators IMPDH1 and the TRKB/BDNF pathway. The project will...
This Project Grant award of $3,510,000.00 from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research conducted by the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, California. The research focuses on understanding the mechanisms underlying melanoma metastasis and resistance, particularly the effects of aging on tumor-intrinsic factors like the UPR signaling component ATF4, as well as tumor-extrinsic...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will fund a research project titled "SESAME: SUN EXPOSURE AND ACTIVITIES AFTER SKIN CANCER: OPTIMIZATION OF MHEALTH INTERVENTIONS". The $331,781 award, effective September 13, 2024 through August 31, 2027, will support Northwestern University in refining and enhancing intervention tools, including a mobile app, to reduce unprotected sun exposure and...
This $716,062 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research to dissect the dasatinib-ome and optimize therapy delivery to address cellular plasticity and therapy resistance in acral melanoma. The primary awardee is The Johns Hopkins University, a private non-profit research university. The university will collaborate with a sub-awardee, Northwestern University, to perform...
This $177,058 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to discover and optimize novel anti-mitotic agents for the treatment of metastatic melanoma. The grant aims to develop fused heterocyclic pyrazine (FHP) based tubulin inhibitors that can overcome drug resistance and reduce toxicity associated with current treatments. The research involves three key...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $673,526.00 to the University of Pittsburgh to conduct research on the role of zinc metabolism in therapy-resistant melanoma. The key focus is to explore how the loss of the p16 gene, which occurs in approximately 40% of melanoma cases, leads to changes in zinc transport and homeostasis that impair the effectiveness of immune checkpoint blockade (ICB) therapy. The research plan aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Dartmouth-Hitchcock Clinic is focused on understanding the role of melanocyte PD-L1 expression in modulating the immune response to UV-induced melanoma. The $635,946 award, with a performance period from July 2024 to June 2029, will support research using an autochthonous mouse melanoma model to investigate how UV radiation-induced interferon-I signaling and tumor inflammatory memory...